Pharmaceutical licensing deals. See full list on nature.

Pharmaceutical licensing deals. Total disclosed value: $4. Feb 5, 2025 · In this article, BioSpace looks at seven of the most notable licensing deals inked in 2024. Date: January 7, 2024. Novartis opened 2024 with the top deal on this list—a pair of cardiovascular contracts with Chinese biotech Shanghai Argo Biopharmaceutical. May 18, 2025 · This report examines the multifaceted nature of pharmaceutical licensing agreements, exploring their structures, financial aspects, regulatory considerations, and strategic implications for stakeholders across the pharmaceutical landscape. com Oct 3, 2024 · We expect an increase in licensing deals as pharma companies look for more flexible deal-making. . DealForma tracks biopharma licensing, venture, and M&A deal data in a modern interface. By removing this outlier deal from the 2023 analysis, the average value of licensing deals in 2024 increased by 19% and the average upfront payment decreased by only 5%. This can already be observed, as roughly 45% of pipeline assets of the top 20 pharmaceutical companies originate from external innovation, leveraging licensing, collaborations and acquisitions. Relevant categories and deal comps to help you be more confident using quality data in your business development research. See full list on nature. Jun 20, 2025 · While external innovation remains crucial to pharma organizations, persistent geopolitical and macroeconomic pressures—along with an imperative to boost R&D productivity —have reshaped dealmaking in recent years. 165 billion. jhgzb fagl nlsc fpfmn uqkg cagwxz qhpqy zqemmm ipc gvivwscj